Evidence map›Paper›PMID 41583492›Full record

ArticleFrontiers in immunology2025

Dissecting the role of KLF5: from tumor progression to immune interactions with emphasis on glioma and bladder cancer.

Ze Yuan, Minyi Situ, Yimeng Ye, Jinhui Zhang, Kuntai Jiang, Shingyik Zhang, Xinpei Deng, Zhenqiang He, Juncheng Luo, Yanjun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ze Yuan *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Minyi Situ *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Yimeng Ye *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Jinhui Zhang *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Kuntai Jiang *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Shingyik ZhangZhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Xinpei DengState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Zhenqiang HeState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Juncheng LuoDepartment of Neurosurgery, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
Yanjun WangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Krüppel-like factor 5 (KLF5) is involved in various aspects of tumor development, metastasis, and drug resistance through their regulation of transcription and translation, yet its functions in a comprehensive cancer framework are still unclear. Methods: Our research involved a detailed pan-cancer analysis using multi-omics data sourced from various public databases. We investigated the clinical characteristics, prognostic significance, mutations, and methylation patterns of KLF5 across various cancer types. Results: We discovered that KLF5 is implicated in tumor progression and are prognostic markers across pan-cancer. KLF5 is significantly linked to various malignant pathways across different types of cancer. Additionally, KLF5 has associations with several immune-related features. Ultimately, experiments were carried out to investigate whether KLF5 could serve as a promising indicator for glioma and bladder cancer. Conclusion: KLF5 may be utilized as a diagnostic tool for cancer, a predictor of its progression, and a guide for treatment., with particular promise as a therapeutic target for glioma and bladder cancer.

Indexed as

GliomaKruppel-Like Transcription FactorsUrinary Bladder NeoplasmsAnimalsBiomarkers, TumorDisease ProgressionDNA MethylationGene Expression Regulation, NeoplasticHumansMutationPrognosisTumor MicroenvironmentBiomarkers, TumorKLF5 protein, humanKruppel-Like Transcription FactorsKLF5multi-omicspan-cancerprognosistumor microenvironment

Identifiers

PMID41583492
PMCPMC12823895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.